Imperial College London

Dr Mark P. Lythgoe

Faculty of MedicineDepartment of Surgery & Cancer

Research Postgraduate
 
 
 
//

Contact

 

m.lythgoe

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lythgoe:2021:10.1016/j.ejca.2021.08.012,
author = {Lythgoe, MP and Prasad, V},
doi = {10.1016/j.ejca.2021.08.012},
journal = {European Journal of Cancer},
pages = {68--70},
title = {How the US Food and Drug Administration’s approval of aducanumab for Alzheimer's disease has implication for oncology and beyond},
url = {http://dx.doi.org/10.1016/j.ejca.2021.08.012},
volume = {157},
year = {2021}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AU - Lythgoe,MP
AU - Prasad,V
DO - 10.1016/j.ejca.2021.08.012
EP - 70
PY - 2021///
SN - 0959-8049
SP - 68
TI - How the US Food and Drug Administration’s approval of aducanumab for Alzheimer's disease has implication for oncology and beyond
T2 - European Journal of Cancer
UR - http://dx.doi.org/10.1016/j.ejca.2021.08.012
UR - https://www.sciencedirect.com/science/article/pii/S0959804921005293?via%3Dihub
UR - http://hdl.handle.net/10044/1/91566
VL - 157
ER -